Legal Representation
Attorney
Emily M. Haas
USPTO Deadlines
Next Deadline
2148 days remaining
Section 8 (6-Year) Declaration Due (Based on registration date 2025-05-27)
Due Date
May 27, 2031
Grace Period Ends
November 27, 2031
Additional deadlines exist. Contact your attorney for complete deadline information.
Application History
50 events| Date | Code | Type | Description |
|---|---|---|---|
| May 27, 2025 | NRCC | E | NOTICE OF REGISTRATION CONFIRMATION EMAILED |
| May 27, 2025 | R.PR | A | REGISTERED-PRINCIPAL REGISTER |
| May 8, 2025 | CNPR | P | ALLOWED PRINCIPAL REGISTER - SOU ACCEPTED |
| May 8, 2025 | SUNA | E | NOTICE OF ACCEPTANCE OF STATEMENT OF USE E-MAILED |
| Mar 24, 2025 | ALIE | A | ASSIGNED TO LIE |
| Mar 24, 2025 | TEME | I | TEAS/EMAIL CORRESPONDENCE ENTERED |
| Mar 24, 2025 | CRFA | I | CORRESPONDENCE RECEIVED IN LAW OFFICE |
| Mar 7, 2025 | TROA | I | TEAS RESPONSE TO OFFICE ACTION RECEIVED |
| Mar 4, 2025 | GNRN | O | NOTIFICATION OF NON-FINAL ACTION E-MAILED |
| Mar 4, 2025 | CNRT | W | SU - NON-FINAL ACTION - WRITTEN |
| Mar 4, 2025 | GNRT | O | NON-FINAL ACTION E-MAILED |
| Jan 18, 2025 | AITU | A | CASE ASSIGNED TO INTENT TO USE PARALEGAL |
| Jan 18, 2025 | SUPC | I | STATEMENT OF USE PROCESSING COMPLETE |
| Nov 4, 2024 | EISU | I | TEAS STATEMENT OF USE RECEIVED |
| Nov 4, 2024 | IUAF | S | USE AMENDMENT FILED |
| Jun 13, 2024 | EXRA | E | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED |
| Jun 4, 2024 | EXT3 | S | SOU EXTENSION 3 FILED |
| Jun 4, 2024 | EX3G | S | SOU EXTENSION 3 GRANTED |
| Jun 4, 2024 | EEXT | I | SOU TEAS EXTENSION RECEIVED |
| Apr 1, 2024 | ARAA | I | ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED |
| Apr 1, 2024 | EWAF | I | TEAS WITHDRAWAL OF ATTORNEY RECEIVED-FIRM RETAINS |
| Apr 1, 2024 | CHAN | I | APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED |
| Apr 1, 2024 | COAR | I | TEAS CHANGE OF OWNER ADDRESS RECEIVED |
| Apr 1, 2024 | TCCA | I | TEAS CHANGE OF CORRESPONDENCE RECEIVED |
| Apr 1, 2024 | REAP | I | TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED |
| Dec 23, 2023 | EXRA | E | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED |
| Dec 21, 2023 | EX2G | S | SOU EXTENSION 2 GRANTED |
| Dec 21, 2023 | EEXT | I | SOU TEAS EXTENSION RECEIVED |
| Dec 21, 2023 | EXT2 | S | SOU EXTENSION 2 FILED |
| Apr 11, 2023 | EXRA | E | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED |
| Apr 7, 2023 | EX1G | S | SOU EXTENSION 1 GRANTED |
| Apr 7, 2023 | EXT1 | S | SOU EXTENSION 1 FILED |
| Apr 7, 2023 | EEXT | I | SOU TEAS EXTENSION RECEIVED |
| Dec 27, 2022 | NOAM | E | NOA E-MAILED - SOU REQUIRED FROM APPLICANT |
| Nov 1, 2022 | NPUB | E | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED |
| Nov 1, 2022 | PUBO | A | PUBLISHED FOR OPPOSITION |
| Oct 12, 2022 | NONP | E | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED |
| Sep 26, 2022 | CNSA | P | APPROVED FOR PUB - PRINCIPAL REGISTER |
| Sep 26, 2022 | XAEC | I | EXAMINER'S AMENDMENT ENTERED |
| Sep 26, 2022 | GNEA | O | EXAMINERS AMENDMENT E-MAILED |
| Sep 26, 2022 | CNEA | R | EXAMINERS AMENDMENT -WRITTEN |
| Sep 26, 2022 | GNEN | O | NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED |
| Sep 14, 2022 | TEME | I | TEAS/EMAIL CORRESPONDENCE ENTERED |
| Sep 14, 2022 | CRFA | I | CORRESPONDENCE RECEIVED IN LAW OFFICE |
| Sep 14, 2022 | TROA | I | TEAS RESPONSE TO OFFICE ACTION RECEIVED |
| Mar 16, 2022 | CEPE | I | COMBINED EXAMINER'S AMENDMENT/PRIORITY ACTION ENTERED |
| Mar 16, 2022 | ALIE | A | ASSIGNED TO LIE |
| Mar 16, 2022 | GEAN | O | NOTIFICATION OF EXAMINER'S AMENDMENT/PRIORITY ACTION E-MAILED |
| Mar 16, 2022 | CPEA | R | EXAMINERS AMENDMENT AND/OR PRIORITY ACTION - COMPLETED |
| Mar 16, 2022 | GEAP | F | EXAMINER'S AMENDMENT/PRIORITY ACTION E-MAILED |
Detailed Classifications
Class 001
Chemical additives derived from microalgae, namely, cyanobacteria, for use in the manufacture of pharmaceuticals, cosmetics, veterinary preparations, and foodstuffs
First Use Anywhere:
Aug 29, 2023
First Use in Commerce:
Aug 29, 2023
Class 005
Vaccine preparations; adjuvants for use with vaccines; therapeutic antibodies for use as immunotherapeutic agents for targeting toxins, viruses and enterotoxic bacteria; biologic preparations for medical and therapeutic purposes, namely, the treatment and prevention of infectious diseases, deficiency diseases, hereditary diseases, physiological diseases, metabolic diseases, autoimmune diseases and gastrointestinal diseases; therapeutic agents for medical purposes, namely, biologic drugs targeted to treat specific diseases, namely, infectious diseases, deficiency diseases, hereditary diseases, physiological diseases, metabolic diseases, autoimmune diseases and gastrointestinal diseases
First Use Anywhere:
Aug 29, 2023
First Use in Commerce:
Aug 29, 2023
Classification
International Classes
001
005
Disclaimers
The following terms have been disclaimed and are not claimed as part of the trademark:
Specific Disclaimer
"BIOSCIENCE"